Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralipid 20% for Recurrent Implantation Failure
NCT02487940Phase 4Completed
- Sponsor
- Dar El Teb Institute
- Start
- Oct 2012
- Primary completion
- Apr 2015
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
A Phase 4 trial of Intralipid 10% in Recurrent Implantation Failure (RIF), sponsored by Dar El Teb Institute. Started Oct 2012; status: completed.
02
Drugs
Intralipid 10%
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on NCT02487940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02487940.